 |
|
Nandrolone Decanoate Therapy for Patients Receiving HemodialysisA Controlled Study
Jesse S. Williams, MD;
Jay H. Stein, MD;
Thomas F. Ferris, MD
Arch Intern Med. 1974;134(2):289-292.
Abstract
A double-blind study was carried out in 18 patients receiving long-term hemodialysis to determine the role of androgen therapy in the anemia of chronic renal failure. Nine patients who received nandrolone decanoate for three months responded with a mean rise in hemoglobin value of 1.2 ± 0.8 gm/100 ml, in hematocrit reading of 4.3 ± 0.8%, and in their red blood cell mass of 325 ± 44 ml. Control groups altered their hemoglobin value 0.1 ± 0.2 gm/100 ml, hematocrit reading 0.4 ± 0.6%, and red blood cell mass 11 ± 66 ml. The differences between these groups were significant at P values<.01,<.001, and <.025, respectively. The data indicate that androgen therapy improves the anemia of chronic renal failure.
Author Affiliations
Columbus, Ohio
From the Department of Medicine, Ohio State University School of Medicine, Columbus.
Footnotes
Submitted for publication April 23, 1973; accepted June 28.
Reprint requests to 410 W Tenth Ave, Columbus, OH 43210 (Dr. Stein).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Significance of 19-norandrosterone in athletes' urine samples
Ayotte
Br. J. Sports. Med. 2006;40:i25-i29.
ABSTRACT
| FULL TEXT
In the erythropoietin era, can we forget alternative or adjunctive therapies for renal anaemia management? The androgen example
Navarro
Nephrol Dial Transplant 2003;18:2222-2226.
FULL TEXT
Transfusion and Long-term Hemodialysis
Crowley et al.
Arch Intern Med 1987;147:1925-1928.
ABSTRACT
Prescribing Medication in Long-term Dialysis Units
Anderson et al.
Arch Intern Med 1982;142:1305-1308.
ABSTRACT
|
